Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells
Ce dossier présente une série d'articles concernant le métabolisme des cellules cancéreuses, notamment les processus métaboliques susceptibles de constituer des cibles thérapeutiques
BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF-mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational strategies for combinatorial treatment.
British Journal of Cancer , article en libre accès, 2019